默沙东PD-1抑制剂可瑞达 （帕博利珠单抗注射液）在华获批原发晚期或复发性子宫内膜癌适应症

Core Viewpoint - Merck's PD-1 inhibitor, Pembrolizumab (brand name: Keytruda), has received approval from the National Medical Products Administration (NMPA) in China for use in combination with Carboplatin and Paclitaxel as a first-line treatment for adult patients with mismatch repair-deficient (dMMR) advanced or recurrent endometrial cancer, followed by Pembrolizumab monotherapy for maintenance treatment. This new indication is based on data from the Phase III clinical trial KEYNOTE-868 (NRG-GY018) [1] Group 1 - Merck's Pembrolizumab has been approved for a new indication in China [1] - The approval is for the treatment of advanced or recurrent endometrial cancer in combination with Carboplatin and Paclitaxel [1] - The new indication is supported by data from the Phase III clinical trial KEYNOTE-868 [1]